Clinical trial
Objective Confirmation of thе Anti-ischemic Effectiveness of Trimetazidine 80mg Once Daily in Patients With Stable Angina Who Had a History of Myocardial Infarction (METHOD)
NCT05210465 is registered in ClinicalTrials.gov with Servier Russia as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Objective Confirmation of thе Anti-ischemic Effectiveness of Trimetazidine 80mg Once Daily in Patients With Stable Angina Who Had a History of Myocardial Infarction (METHOD)
- Lead sponsor
- Servier Russia
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 3, 2022
- Completion date
- April 17, 2024
- Enrollment
- 36 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.